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Background: Reports in the literature regarding the effect of antiretroviral therapy on 
pregnancy outcomes are conflicting and are largely from cohorts in the developed world. 
Methodology: A retrospective cohort study of all deliveries in King Edward VIII Hospital 
(KEH) Durban, South Africa, from 1st of March 2013 to 30th of June 2013 was conducted 
Aims/Objectives: 1.To describe the demographic profiles of women with HIV on 
HAART;2.To estimate the risk of preeclampsia in HIV positive women on HAART;3.To 
determine the prevalence of post-partum hemorrhage in HIV positive women on 
HAART;4.To determine the prevalence of chorioamnionitis in HIV positive women on 
HAART;5.To determine the prevalence of preterm delivery either iatrogenic or spontaneous 
in HIV positive women on HAART;6.To determine neonatal outcome and  prevalence of low 
birth weight at term in neonates of HIV positive women on HAART 
Results: There were 970 HIV positive women (39.3%) and 1496 HIV negative (60.7%).HIV 
Positive women on antiretroviral therapy had lower odds for developing preeclampsia (7.9% 
vs 12.9%, P< 0.001), abruptio placentae (1.0% vs 2.5%, P =0.003) gestational diabetes 
mellitus (0.3% vs 1.3%, P = 0.01), than HIV negative women. Women on antiretroviral 
medications were more likely to have preterm premature rupture of the membranes 
(PPROM) (5.6% vs 3.4%, P=0.01) and chorioamnionitis (0.95% vs 0.27%, P= 0.02) than HIV 
negative women. There were no differences in maternal outcomes including chronic 
hypertension (1.1% vs 1.8%, P =0.87) and gestational hypertension (4.0% vs 3.2% P = 0.33). 
The odds of having postpartum haemorrhage was not different between the two groups 
(2.5% vs 3.2%, P = 0.25) for HIV positive women on antiretroviral medications and HIV 
negative women respectively. There was no difference in the prevalence of preterm delivery 
at less than 37 weeks of gestation (17.8% vs 19.9%, P = 0.19), and preterm delivery at less 
than 34weeks of gestation (8.7% vs 7.6%, P = 0.32) between HIV positive women on 
antiretroviral medication and HIV negative women. Neonatal outcomes including 5-min 
APGAR score <7(1.9% vs 1%, P = 0.08) intraventricular hemorrhage (0.4% vs 0%, P = 0.05) 
respiratory distress syndrome (7.7% vs 6.9% P = 0.47), neonatal pneumonia (1.4% vs 2.3% P 
=0.08), necrotising enterocolitis (0.1% vs 0%, P= 0.52), and culture proven sepsis (1.2% vs 





 HIV positive women on antiretroviral therapy are at lower risk of adverse maternal 
outcomes such as preeclampsia, abruptio placentae, and gestational diabetes mellitus. 
There is no difference in the risk of perinatal complications like 5-min APGAR score < 7, and 
delivering low birth weight babies between HIV positive and HIV negative women. However, 
















INTRODUCTION AND LITERATURE REVIEW 
Antiretroviral therapy (ART) is effective in improving maternal health as well as in 
prevention of mother-to-child transmission (PMTCT) in human immunodeficiency virus (HIV) 
infected women [1, 2]. Reports in the literature regarding the outcome of pregnancies in 
women seropositive for HIV on antiretroviral therapy are conflicting and are largely from 
cohorts in the developed world [3-7]. Two million pregnancies occur every year in HIV-
infected women, most of whom are in sub-Saharan Africa[8, 9]. This region accounts for 
two-thirds of the 34million people living with HIV globally[9, 10] and a large number of 
women infected with HIV are  now on highly active antiretroviral therapy(HAART) in 
pregnancy[9, 10]. This is as a result of concerted efforts by the international community to 
support attainment of universal access to HAART. The World Health Organization (WHO) 
recommended, in 2010, that all individuals infected with HIV, with a CD4 count ≤ 350cells/ 
mm3 ; and all pregnant women with WHO clinical stage 3 or 4 disease, independent of CD4 
cell count, should be commenced on HAART[9]. This recommendation was revised by the 
WHO in 2013 where the guidelines now recommend that option B+ be implemented by all 
countries and where this is  impossible, option B. Option A  should only be implemented as 
last alternative[11].  
In Option B+, all pregnant women infected with HIV are given HAART for the entire duration 
of pregnancy, labour, delivery and breastfeeding and they continue lifelong, irrespective of 
CD4 count or clinical stage of the disease. On the other hand, in Option B, HAART is taken 
throughout pregnancy and continued for life only if CD4 count is ≤350cells/mm3 beginning 
as soon as diagnosis of HIV infection is made. Pregnant women with CD4 count 
>350cells/mm3are given HAART from 14weeks of pregnancy and continue through labour 
and delivery, if baby is not breastfed, or until 1 week after breastfeeding ends. In Option A, 
Pregnant women receive HAART throughout pregnancy, labour and delivery and continue 
for life, again only, if CD4 count≤ 350cells/mm3 as in option B above. Women with CD4 
count > 350cells/mm3 receive azidothymidine (AZT) from 14weeks gestation and single dose 
nevirapine(NVP) as well as first dose azidothymidine/lamivudine(AZT/3TC) at the beginning 




antiretroviral therapy either because of low count of CD4 or advanced clinical stage of the 
disease, have HAART for life[11]. However, eligibility for HAART for life is to be determined 
by individual country. A  CD4 count of ≤ 500 cells/mm3 (or clinical stage 3 or 4 disease)  is 
recommended by WHO as eligibility criteria for HAART for life[11].  
The combination of tenofovir plus lamivudine (or emtricitabine) plus efavirenz is the first-
line treatment regimen for HIV-infected pregnant and breastfeeding women. It is made 
available   as a fixed-dose combination(FDC) and  it is affordable[11, 13]. This regimen is also 
well tolerated and safe for both pregnant and breastfeeding women and their infants. 
Monitoring requirements and drug-resistance profiles are low for this regimen [14-16]. It 
can be administered  together with other drugs used in the clinical care of HIV-infected 
population including non-pregnant adults[17, 18]. It is simple, affordable and taken as a 
once daily regimen and also has efficacy against hepatitis B virus (HBV) [11, 13, 19-22]. 
 The goals of treatment with HAART include: minimization of morbidity associated with HIV 
and improvement in life expectancy and quality of survival [23-26]; prevention of HIV 
transmission[27-32]; maximum and prolonged viral load suppression; and restoration and 
preservation of immunological function[33, 34].The changes in the immune system during 
pregnancy are well documented. The absolute number as well as the percentage CD4 count  
have been reported to drop in pregnancy and return to their pre-pregnancy range within 
four months post-delivery[35, 36]. The consequence of this on HIV-infected pregnant 
women is uncertain. Some studies report a deterioration of  immune function during 
pregnancy[37, 38] and others report no important effect of pregnancy on immune function 
[39, 40]. Studies before the advent of the use of HAART by large numbers of HIV-infected 
pregnant women demonstrated that there was  either only slight increase or no effect on 
HIV disease progression attributable to pregnancy [38, 41-45] Pregnancy may be associated, 
though not strong, with HIV disease progression as demonstrated by a  systematic review 
and meta-analysis[46].   
HIV disease progression has been shown to be decreased by HAART[47, 48].There is an 
association of a marked decrease in morbidity and mortality rates in populations infected 
with HIV with the use of HAART [49].However, it is also known that use of HAART by 




4, 6, 50-53]. There are also reports of increased risk of preeclampsia, fetal death [52, 54, 55], 
low birth weight[56] and gestational diabetes mellitus[57] with HAART. Maternal 
complications including hepatic failure and lactic acidosis, though uncommon, have been 
recognised as complications of HAART, especially with increased duration of use[58]. 
Pregnancy may also exacerbate the risks of other side effects of HAART such as vomiting 
and anaemia[59]  
Antenatal HIV infection prevalence is particularly high in South Africa at 39.5%[60].Non-
pregnancy related infections, mainly due to HIV and acquired immunodeficiency 
syndrome(AIDS) have been reported as the most common cause of maternal mortality, 
constituting 43.7% of all maternal deaths in South Africa[61]. Maternal HIV infection is 
associated with post-partum endometritis and a tendency to a higher stillbirth 
rate[62].Pregnant women infected with HIV appear to be at significantly higher risk of 
unfavourable pregnancy and  infant outcomes than women seronegative for HIV. These 
adverse outcomes include increased incidence of miscarriage, fetal abnormality, premature 
delivery, low birth weight babies, perinatal, neonatal and infant mortalities.[63, 64] 
These adverse pregnancy outcomes have not been documented in our local population 
where up to 40.3% of women delivering in our health facilities are HIV 
positive[60].Therefore, we sought to estimate  the risk of adverse  pregnancy outcomes in 










2.1   METHODOLOGY 
A retrospective cohort study of all deliveries in King Edward VIII Hospital (KEH) from 1st of 
March 2013 to 30th of June 2013 was conducted. 
 King Edward the VIII hospital serves predominantly patients from low socioeconomic 
circumstances in the Durban area of KwaZulu-Natal. Standard practice at the time of this 
study was for all women at their first antenatal booking visit to have counselling and testing 
for HIV. Women who were HIV positive had their bloods tested for CD4 count levels. HIV 
viral load was not routinely tested. 
The department of health policy on antiretroviral therapy at the beginning of the data 
collection period was the implementation of WHO option B as discussed above. Towards the 
end of the data collection period the policy was changed to option B+ in line with the WHO 
recommendations.   
 
2.2 AIMS/OBJECTIVES 
1. To describe the demographic profiles of women with HIV on HAART 
2. To estimate the risk of developing preeclampsia in women seropositive for HIV on 
HAART 
3. To determine the prevalence of post-partum haemorrhage in women seropositive 
for HIV on HAART 
4. To determine the prevalence of chorioamnionitis in HIV-infected women on HAART 
5. To determine the prevalence of preterm delivery either iatrogenic or spontaneous in 
women seropositive for HIV on HAART 
6. To determine the neonatal outcome and prevalence of low birth weight at term in 




2.3 INCLUSION CRITERIA  
All mothers who delivered after 26weeks of gestation from 1st of March 2013 to 30th of June 
2013 were included. This included all women seropositive and seronegative for HIV 
Women seropositive for HIV on HAART initiated either before or during the index pregnancy 
were included. 
2.4 EXCLUSION CRITERIA 
 All women delivering before 26 weeks of gestation were excluded as well as those that had     
multiple gestations.  
HAART refers to the use of three or more antiretroviral agents (either as fixed dose 
combination or individual agents) concomitantly for the purpose of aggressive reduction in 
viral load and improvement of patient’s CD4 cell count.  
HIV positive mothers who took antiretroviral drug or drugs in the index pregnancy for the 
purpose of prevention of vertical transmission were also included. This includes women who 
used azidothymidine (AZT) from 14weeks of gestation or later, single dose nevirapine and 
tenofovir/emtricitabine at the onset of labour (Dual therapy).   
 
2.5 DATA COLLECTION  
Discharge register in labour ward was used to get inpatient numbers of mothers, and of 
their babies, that delivered during the study period, 1st March 2013 to 30th June 2013. 
Charts of women and, of their babies, delivering in King Edward VIII Hospital during this 
period were retrieved from medical records department and a detailed chart review was 
performed.  
Data collection using a data sheet designed for the purpose of this study was undertaken 
Demographic data were obtained from antenatal records together with inpatient admission 
history. Gestational age at time of delivery was obtained from patient’s chart calculated 




ultrasound estimation of gestational age or estimates of gestation based on the earliest 
palpation as documented in the patient’s chart were used.  The use of drugs of abuse, 
smoking, or alcohol use was obtained from patients’ charts as self-reported by the patient. 
HIV status was confirmed by review of serological test result documented in patient’s ante 
natal record. 
Adverse obstetric outcomes examined include: preterm delivery iatrogenic or spontaneous, 
(defined as delivery before 37 weeks of gestation), gestational hypertension, preeclampsia 
(as defined by the International Society for the Study of Hypertension in Pregnancy (ISSHP) 
guidelines), gestational diabetes mellitus either treated by dietary control or requiring 
hypoglycaemic agents, including either insulin or oral hypoglycaemic agents or both.  
Post-partum outcomes investigated included: post-partum haemorrhage (as documented 
diagnosis by attending health care practitioner) and this was defined as blood loss >500ml at 
vaginal delivery or >1000ml at caesarean section. 
Neonatal outcomes were obtained from delivery and neonatal inpatient records. Outcomes 
included: low birth weight (<2500g), small for gestational age (birth weight <10th percentile) 
macrosomia (birth weight >90th percentile), Apgar score <7 at 1 or 5minutes, culture proven 
sepsis, pneumonia, respiratory distress syndrome, intraventricular haemorrhage, and 
neonatal jaundice 
2.6. Ethical Considerations 
Approval was obtained from the Chief Executive Officer of King Edward VIII Hospital (KEH 
VIII) for permission to retrieve and analyse patients’ records. 
Ethics approval was obtained from the Biomedical Research Ethics Committee (BREC) of the 
University of KwaZulu-Natal. Ref: BE069/13 
2.7. SAMPLING 
A total of 2570 deliveries occurred from the period 1st March 2013 to 30th June 2013. Two 
thousand five hundred and thirty-four charts of mothers were retrieved. Thirty-six charts 




they were for mothers with twin pregnancies. A total of 2466 charts of mothers and 2420 
charts of their babies were reviewed. There were a total of 46 singleton stillbirths during the 
study period. Twenty-four HIV positive women did not receive any form of antiretroviral 
therapy and were not included in the study.   
2.8. STATISTICAL ANALYSIS 
The data was entered in Microsoft Excel and subsequently analysed in Intercooled Stata 
13.0 (Stata Corporation, College Station, TX, United States) Descriptive statistics such as 
frequencies, percentages, means and standard deviations were used to summarize sample 
results. Pearson chi-squared test or Fisher’s exact tests were used to test if there was any 
association between categorical pregnancy outcomes in women seropositive for HIV on 
antiretroviral medication and women seronegative for HIV. Two- sample Wilcoxon rank-sum 
(Mann-Whitney) test was used for continuous variables such as age and birth weight. 
Logistic regression was performed to calculate the odds ratio of adverse outcomes 
(maternal and neonatal) for the HIV infected women on ARVs compared with the HIV 
negative women and reported with 95% confidence intervals. Subgroup analysis of women 
on antiretroviral medications was further performed by logistic regression for various 









3.1   Maternal Demographics and Antiretroviral Therapy of the Study 
Cohort 
During the study period 1st March to 30th June 2013 a total of 2570 women gave births at or 
after 26weeks gestation at KEH. Thirty-six charts could not be retrieved (missing). Charts 
were retrieved for 2534 women and 68 of these had multiple gestations and were excluded 
from the analysis. Twenty-four HIV positive women did not use antiretroviral medications 
and were excluded from the study. The ages ranged from 14 - 45yrs for the 2466 women 
who were included in the study. 
There were 1496 HIV negative (60.7%) and 970 HIV positive women (39.3%). One thousand 
four-hundred and fifty-nine (97.5%) of the women in the study were Africans. There were 18 
Indian women (0.7%), 9 coloured women (0.4%), 6 white women (0.2%) and 4 women 
(0.2%) of other races. All HIV positive women in the study were Africans. 
Women seropositive for HIV were significantly older and of higher parity than the HIV 
seronegative mothers (Table1). Smoking and alcohol use were similar for both groups. A 
total of 946 women used antiretroviral medications in the study cohort. Two hundred and 
nine women (22.1%) commenced highly active antiretroviral therapy before they found out 
that they were pregnant 
Four hundred and seventeen HIV positive women (44.1%) used a combination of efavirenz, 
tenofovir and lamivudine regimen while 335 women (35.4%) used azidothymidine and 
intrapartum nevirapine (dual therapy). One hundred and twenty five women (13.2%) used a 
combination of efavirenz, tenofovir and emtricitabine (FDC). Only four women (0.4%) used 




3.2   Maternal Outcomes 
HIV positive women had lower odds for developing preeclampsia (7.9% vs 12.9%, P< 0.001), 
abruptio placentae (1.0% vs 2.5%, P =0.003), gestational diabetes mellitus (0.3% vs 1.3%, P = 
0.01), than HIV negative women (Table 3). Women seropositive for HIV were at increased 
risk of preterm premature rupture of the membranes (PPROM) (5.6% vs 3.4%, P=0.01) and 
chorioamnionitis (0.95% vs 0.27%, P= 0.02) compared to women seronegative for HIV (Table 
3).Maternal outcomes including chronic hypertension (1.1% vs 1.8%, P =0.87), gestational 
hypertension (4.0% vs 3.2% P = 0.33), were not different between women seropositive for 
HIV and HIV seronegative women. The odds of having postpartum haemorrhage was not 
different between the two groups (2.5% vs 3.2%, P = 0.25) for women seropositive for HIV 
on antiretroviral medications and women seronegative for HIV respectively (Table3). 
 
3.3    Neonatal Outcomes 
HIV seropositive women on antiretroviral medication were at higher odds of having SGA 
(<10th percentile) babies (11.3%vs 9.0% P = 0.002) than women seronegative for HIV (Table 
4).There was no difference in the prevalence of preterm birth before 37 weeks of gestation 
(17.8% vs 19.9%, P = 0.19), and preterm delivery at less than 34weeks of gestation (8.7% vs 
7.6%, P = 0.32) between women seropositive for HIV and HIV seronegative women (Table 4). 
Women seropositive for HIV were less likely to deliver babies with APGAR scores in 1-
minute <7(5.6% vs 9.3%, P = 0.001) than women seronegative for HIV (Table4). Babies of  
women seropositive for HIV were at lower odds of developing neonatal jaundice than babies 
of women seronegative for HIV (9.2% vs 14.6%, P < 0.001).Neonatal outcomes including 5-
min APGAR score <7(1% vs 1.9%, P = 0.08) intraventricular haemorrhage (0% vs 0.4% , P = 
0.05) respiratory distress syndrome (6.9% vs 7.7%, P = 0.47), neonatal pneumonia (2.3% vs 
1.4%, P =0.08), necrotising enterocolitis (0.0% vs 0.1%, P= 0.52), and  culture proven 




3.4   Subgroup Analysis 
Logistic regression was performed and it was shown that preeclampsia was more likely to 
occur in women who were HIV-uninfected when compared with women who were HIV-
infected and receiving antiretroviral medications (Table 5) 
Subgroup analysis of HIV positive women on antiretroviral therapy was performed 
comparing various adverse outcomes for these subgroups with HIV negative women and the 
results are shown (Table 6 and Table7).The subgroups analysed were HIV-infected women 
on dual therapy and HIV-infected women on pre-pregnancy HAART.  
 The higher odds of HIV negative women developing preeclampsia  compared to HIV positive 
women on antiretroviral therapy disappears when the comparison is made between the 
subgroup of HIV positive women on dual therapy and women seronegative for HIV (Table 6). 
However, there is a stronger association between being seronegative for HIV and increased 
risk for developing preeclampsia when HIV positive women who commenced HAART before 
















DEMOGRAPHIC CHARACTERISTICS OF WOMEN IN THE STUDY 
Characteristics Group 










Parity(range) 0-6 0-5  
Para 0 193(20.4%) 741(49.5%) <0.001 
Para ≥1 753(79.6%) 755(50.5%) <0.001 
Race    
African 970(100%) 1459(97.5%)  
Indian - 18(1.2%)  
Coloured - 9(0.6%)  
White - 6(0.4%)  
Other - 4(0.3%)  
Marital status    
Single 896(92.4%) 1348(90.1%) 0.06 
Married 74(7.6%) 148(9.9%) 
Employment  status 
 
   
Unemployed 805(82.9%) 1306(87.3%) 0.003 
Employed 165(17.1%) 190(12.7%) 
Smoking 6(0.6%) 17(1.1%) 0.19 
Alcohol 5(0.5%) 8(0.5%) 0.95 
Immunological    
HIV  serology 970(39.3%)b 1496(60.7%)e  
Median CD4(cells/mm3 358(2-1873)c NA  
Median gestational age at 
Which CD4 was taken(weeks) 
20 NA  
Prepregnancy HAART 209(22.1%)d NA  









aMedian age and range of the groups 
bPercentage of study cohort 
cMedian and range of CD4 count 
dPercentage of HIV positive women on Prepregnancy HAART 





















ANTIRETROVIRAL (ARV) MEDICATION-USE BY STUDY COHORT 
ARV Group 




Efavirenz/lamivudine/tenofovir 417(44.1%) NA 




Efavirenz/emtracitabine/tenofovir(FDC) 125(13.2%) NA 
Azidothymidine +intrapartum nevirapine 
+ emtricitabine + tenofovir(dual therapy) 
335(35.4%) NA 
Nevirapine only 12(1.3%) NA 
Other regimen 25(2.6%) NA 
Prepregnancy HAARTa 2-09(22.1%) NA 

















Preeclampsia 75(7.9%) 193(12.9%) <0.001 
Gestational hypertension 38(4.0%) 48(3.2%) 0.33 
Chronic hypertension 27(1.8%) 11(1.1%) 0.87 
Gestational diabetes 3(0.3%) 20(1.3%) 0.01 
Preterm Premature Rupture of membranes 
(PPROM) 
53(5.6%) 51(3.4%) 0.01 
Chorioamnionitis 9(0.95%) 4(0.27%) 0.02 
Abruptio placentae 10(1.0%) 38(2.5%) 0.003 
Post-partum haemorrhage 24(2.5%) 49(3.2%) 0.25 












Preterm deliveries <37weeks    
Total 168(17.8%) 298(19.9%) 0.19 
Spontaneous 113(11.9%) 187(12.5%) 0.09 
Preterm deliveries <34weeks    
Total 82(8.7%) 113(7.6%) 0.32 
Spontaneous 43(4.5%) 52(3.5%) 0.55 
Birth weight(g)a 3036±653 3044±640 0.76 
Term low birth weight(<2500g) 47(5.0%) 56(3.7%) 0.14 
Small for gestational age(<10th percentile) 107(11.3%) 136(9.0%) 0.002 
1min APGAR score<7 53(5.6%) 136(9.0%) 0.001 
5min APGAR score<7 9(1.0%) 27(1.8%) 0.08 
Intraventricular haemorrhage(IVH) 0(0.0%) 6(0.4%) 0.05 
Respiratory Distress Syndrome(RDS) 66(7.0%) 113(7.6%) 0.47 
Neonatal jaundice 88(9.3%) 214(14.3%) <0001 
Neonatal pneumonia 22(2.3%) 20(1.3%) 0.08 
Necrotizing enterocolitis(NEC) 0(0.0%) 1(0.1%)  0.52 
Culture proven sepsis 12(1.3%) 18(1.2%) 0.92 
amean ± standard deviation 
Two –sample Wilcoxon rank- sum (Mann-Whitney) and Pearson Chi square tests were used 






ADVERSE MATERNAL/NEONATAL OUTCOMES IN HIV POSITIVE WOMEN WHO RECEIVED 
ANTIRETROVIRAL MEDICATIONS 
Outcomes in women seropositive for HIV 
on  ARVs 
OR 95% CI 
Preeclampsia 0.6 0.4-0.8 
Abruptio placentae 0.3 0.2-0.7 
Post-partum haemorrhage(PPH) 0.8 0.5-1.3 
Chorioamnionitis 3.6 1.1-11.7 
Low birth weight(<2500g) 1.1 0.9-4.2 
5min APGAR score<7  1.9 0.9-4.2 
Culture proven sepsis 1 0.5-2.2 
Maternal and neonatal outcomes in women seropositive for HIV on antiretroviral 
medications were compared with outcomes in HIV seronegative women 









ADVERSE MATERNAL/NEONATAL OUTCOMES IN HIV POSITIVE WOMEN WHO RECEIVED 
DUAL THERAPY 
Outcomes  OR 95% CI 
Preeclampsia 1.1 0.8-1.6 
Abruptio placentae 0.9 0.4-2.0 
Post-partum haemorrhage 0.5 0.2-1.2 
Chorioamnionitis 3.3 0.7-14.9 
Low birth weight(<2500g) 1.1 0.9-1.4 
5min APGAR score < 7 0.8 0.5-1.3 
Culture proven sepsis 1.5 0.6-3.7 
Maternal and neonatal outcomes in HIV positive women who received dual 
therapy(Azidothymidine from 14 weeks gestation and intrapartum azidothymidine + 
intrapartum single dose nevirapine and a combination of emtricitabine + tenofovir) were 
compared with outcomes in HIV negative women 
Logistic regression was performed, the odds ratio calculated and reported with the 95% 






ADVERSE MATERNAL/NEONATAL OUTCOMES IN WOMEN WHO COMMENCED HAART PRIOR 
TO PREGNANCY 
Outcome OR 95% CI 
Preeclampsia 0.2 0.1-0.5 
Post-partum haemorrhage(PPH) 1.6 0.8-3.2 
Chorioamnionitis 5.4 1.2-24.4 
Low birth weight(<2500g) 1.1 0.7-1.6 
5min APGAR score < 7 0.3 0.1-0.7 












The prevalence of HIV in our study cohort of 2466 women was 39.3%, which is similar to the 
antenatal HIV seroprevalence of 39.5 % reported by the South African national department 
of Health[60]. We demonstrated that women seropositive for HIV on antiretroviral therapy 
are at a lower risk of developing maternal complications such as preeclampsia, abruptio 
placentae and gestational diabetes mellitus compared to women seronegative for HIV. 
There is no difference in the risk of perinatal complications like 5-minute APGAR score < 7 
between women seropositive for HIV on antiretroviral therapy and HIV seronegative 
women. However, women seropositive for HIV on HAART are at increased risk of developing 
chorioamnionitis, and showed a trend towards increased risk of delivering babies with low 
birth weight, compared to women seronegative for HIV.   
 
In our study cohort, women seropositive for HIV on antiretroviral therapy with a median 
CD4 of 358cells/mm3 (2-1873) have a significantly lower odds (40% less) of developing 
preeclampsia (OR 0.6, 95% CI 0.4-0.8) when compared to women seronegative for HIV. The 
relationship between antiretroviral therapy and reduced risk of preeclampsia is even 
stronger when the comparison is between women who commenced HAART prior to 
pregnancy and women seronegative for HIV (OR 0.2, 95% CI 0.1-0.05).  This association 
disappears when only women on dual therapy were compared with HIV negative women 
(OR 1.1, 95% CI 0.8-1.6). There are conflicting reports in the literature regarding the effect of 
HIV and HAART on the risk of development of preeclampsia. Suy et al[54] in their 
retrospective study carried out in Barcelona, Spain, found that there was increased rate of 
preeclampsia and fetal death in women seropositive for HIV  treated with HAART. Their 
study is different from ours in that they had a predominantly white study population (85%) 
compared to our study population that is 100% black Africans that are seropositive for HIV.  
 Mattar et al[65] on the other hand found lower rates of preeclampsia in women 
seropositive for HIV on HAART compared with women seronegative for HIV. Their study was 




count of 531 cells/mm3 (200- 1378) receiving monotherapy or HAART and 1708 HIV negative 
controls. They reported a significantly lower rate of preeclampsia among women 
seropositive for HIV on antiretroviral therapy compared to healthy controls (0.8% vs 10.6%, 
P = 0.002). 
  
Boyajian et al [66] carried out a retrospective matched cohort study including 273 women 
seronegative for HIV and  91 women seropositive for HIV  on HAART and demonstrated that 
women seropositive for HIV on HAART are not at increased risk of developing 
preeclampsia(3.3% vs 5.1%, adjusted odds ratio[aOR] 0.59, 95% CI 0.89-5.24).   
 Haeri et al [67], in their study including 151 women seropositive for HIV on HAART and 302 
women seronegative for HIV, also found that  women seropositive for HIV on HAART had 
lower rates of preeclampsia compared with women seronegative for HIV (6% vs 12%, P= 
0.04). However, after corrections for differences in smoking and cocaine use were made, 
the difference between the two groups did not reach statistical significance [aOR 0.55, 95% 
CI 0.26- 1.2]. The study was also a retrospective cohort study similar to ours. The difference 
between our study and the study by Haeri et al is that they had a very small sample size and 
there were statistically significant differences in cigarette smoking ( 7% vs 25%, P<0.001) 
and cocaine use(1% vs 7%, P< 0.001) between the groups  with higher rates in women 
seropositive  for HIV on HAART in  their study. The rates of smoking were 0.6% vs 1.1%, P = 
0.19 in women seropositive for HIV and women seronegative for HIV respectively in our 
study. 
 
Wimalasundera et al[55], showed in a prospective cohort study including 214 women 
seropositive for HIV (stratified into untreated, mono, dual and triple therapy) and 214 
women seronegative for  HIV, that untreated women seropositive for  HIV had lower rates 
of preeclampsia than treated women. They concluded that the immune restorative effect of 
triple antiretroviral therapy is responsible for the lower rates of preeclampsia in the 




The plausible explanation for the lower rate of preeclampsia in women seropositive for HIV 
on HAART compared to women seronegative for HIV demonstrated in our study, could be 
because the immune system plays a role in the aetiology of preeclampsia such that 
conditions of relative immune deficiency partially prevents the development of 
preeclampsia[68].  
This postulation also explains the higher rates of preeclampsia in treated compared to 
untreated HIV seropositive women observed by Wimalasundera et al. Our observations that 
women on dual therapy showed a trend towards increased risk of preeclampsia (OR 1.1, 
95% CI 0.8-1.6); as opposed to  women seropositive for HIV who commenced HAART before  
pregnancy(OR 0.2, 95% CI 0.1-0.5) can further be explained by this postulation.  
Women who received dual therapy had higher CD4 counts (> 350cells/mm3) than those who 
received HAART. Women who commenced HAART prior to pregnancy were women who 
needed HAART for their own health and so had lower CD4 counts than those who 
commenced HAART in pregnancy. This means the higher the degree of immunosuppression, 
the lower the rates of preeclampsia. 
We demonstrated that there was no significant difference in the incidence of postpartum 
haemorrhage between women seropositive for HIV on HAART and women seronegative for 
HIV in our study cohort. Data comparing the prevalence of postpartum haemorrhage 
between women HIV positive women on HAART and HIV negative women are sparse in the 
literature. Our finding is similar to that of  Azria et al [69]. In their retrospective cohort 
study, including 146 women in each group, comparing the term labour management and 
outcomes of treated HIV positive to HIV negative women, they demonstrated that  the 
incidence of postpartum haemorrhage (12.3% vs 18.5%, P = 0.12) was not significantly 
different between the two groups. 
A recent systematic review and meta-analysis by Calvert et al [70]is in concordance with our 
finding. Their systematic review of 44 studies on HIV and risk of direct obstetric 
complications including 17dataset on obstetric haemorrhage suggested that there was no 
increase in odds of postpartum haemorrhage in women for HIV positive women compared 
to women seronegative for HIV. This finding is important if we consider the fact that 




Africa, non-pregnancy related sepsis mainly due to HIV and AIDS is the leading cause of 
death[61]. It means therefore that HIV positive on antiretroviral medications compared to 
HIV uninfected women are not at further increased risk of adverse pregnancy outcome as 
far as postpartum haemorrhage is concerned. This finding, however, should be interpreted 
with caution as our study is retrospective and postpartum haemorrhage in this study is 
taken as documented by the attending health care practitioner at delivery. There are 
inherent difficulties in estimating blood loss both at caesarean section and at vaginal 
delivery as most often it is done by visual estimation and there is a real possibility of under 
reporting.  
  
Women seropositive for HIV on antiretroviral medications were nearly four times more 
likely to have chorioamnionitis compared to women seronegative for HIV (OR 3.6 95% CI 
1.1-11.7). Our finding is similar to the those of Musana et al [72]who demonstrated, in a 
prospective cohort study including 68 HIV positive women with advanced disease(WHO 
stage 3 and 4) and 68 HIV negative women, that chorioamnionitis was more likely to occur 
in the HIV infected women(14.8% vs 2%  P = 0.004). Our finding is also consistent with the 
findings of Cavert et al [70]. In their systematic review and meta-analysis they suggested 
that women seropositive for HIV were more likely to develop intrauterine infections than 
women seronegative for HIV. Our finding is biologically plausible because HIV seropositive 
women being of lower immunity are more prone to developing infections[73]. 
We did not demonstrate any association between HIV and either iatrogenic or spontaneous 
preterm birth. The prevalence of preterm birth, before 37 weeks of gestation, amongst 
women seronegative for HIV was 19.9% compared to 17.8% for HIV seropositive women on 
antiretroviral medication,  P=0.19. The prevalence of spontaneous preterm birth occurring 
before 37 weeks of gestation was 11.9 vs 12.5%, P= 0.09 for women seropositive for HIV and 
seronegative women respectively. Similarly the prevalence of preterm birth occurring 
before 34 weeks of gestation was not significantly different between women seropositive 
for HIV and seronegative women. The prevalence of preterm birth before 34 weeks of 
gestation was 8.7% vs 7.6, P=0.32 for HIV seropositive women and HIV seronegative women 




3.5%, P=0.55 for women seropositive for HIV and seronegative women respectively. Our 
finding is similar to findings of Ndirangu et al[74]. Their study was a non-randomized 
intervention cohort study in Northern KwaZulu-Natal including 2368 live born singletons. 
They demonstrated that there was no association between HIV and preterm births.  
Our finding is also consistent with the findings of a systematic review and meta-analysis by 
Kourtis et al which showed that combination antiretroviral therapy use compared with no 
treatment is not associated with increased risk of preterm births [6]. 
 
Our finding differs from other reports in the literature regarding the effect of antiretroviral 
therapy on preterm birth, where antiretroviral therapy has been linked with increased risk 
of preterm births. Cotter et al[75]  suggest, in their prospective study that protease inhibitor 
(PI) based HAART rather than monotherapy or non-PI based HAART was associated with 
preterm delivery. Watts et al[76] also concluded that use of protease inhibitor in early 
gestation was linked with increased risk of  preterm birth. van der Merwe K et al [77] 
suggest that use of non-nucleoside reverse transcriptase inhibitor (NNRTI) based HAART is 
linked with increased risk of preterm birth. These studies compared preterm births between 
HIV seropositive women on HAART (or a particular regimen) with HIV seropositive women 
on no treatment or another regimen. Their hypothesis was that there was an immunological 
basis for the observation of increased preterm delivery in women on HAART. HIV disease 
progression is linked with an increase in Th2 cytokines level and a suppression of Th1 
cytokines as observed in normal pregnancy[78]. HAART reverses this  increased Th2 to Th1  
cytokine ratio [78].  
 
Although, the study by Ndirangu et al [74]was carried out at a time when HAART was not 
widely used by pregnant women, their findings are in concordance with ours. A prospective 
cohort study in a setting such as ours is needed to investigate the effect of antiretroviral 
therapy on preterm delivery.   
Our study found that women seropositive for HIV on antiretroviral therapy are not at 




Merwe et al [77].Our findings , however, differ from the findings of Machado et al [79] who 
found that women seropositive for HIV on HAART were at increased risk for delivering low 
birth weight babies than the general population. Their study was prospective cohort 
including 696 HIV positive women on antiretroviral medications in Rio de Janeiro. The 
difference between our finding and that of Machado et al could be because of the relatively 




4.2 LIMITATIONS OF THE STUDY 
This is the first study in our local population comparing pregnancy outcomes in women 
seropositive for HIV on HAART with uninfected women. 
Our study was retrospective and so findings must be interpreted in this context. Many of the 
outcomes analysed were as documented by attending physicians. There is possibility of 
some diagnoses being over- or under- diagnosed. We were unable to explore the 
psychosocial factors that could impact pregnancy outcomes adversely because of the 
retrospective nature of our study. Smoking, alcohol and illicit drug use were as self-reported 
by the patient. It is also possible that there was underreporting of use of these substances. 









CONCLUSION AND RECOMMENDATION 
HIV positive women on antiretroviral therapy are at lower risks for developing adverse 
pregnancy outcomes such as preeclampsia, abruptio placentae and gestational diabetes 
mellitus compared to HIV negative women. Perinatal complications like 5-minute APGAR 
score <7 and delivering low birth weight babies are not different between HIV positive 
women and uninfected women. However, women seropositive for HIV are at increased risk 
of developing chorioamnionitis compared to women seronegative for HIV. We have 
demonstrated that the use of HAART in pregnancy is not associated with increased risk of 
adverse outcome 
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D. REVISED WHO CLINICAL STAGING OF HIV/AIDS FOR ADULTS AND 
ADOLESCENTS 
 
Primary HIV infection 
Asymptomatic 
Acute retroviral syndrome 
 
 
Clinical stage 1 
Asymptomatic 
Persistent generalized lymphadenopathy (PGL) 
 
Clinical stage 2 
Moderate unexplained weight loss (<10% of presumed or measured body weight) 




Recurrent oral ulcerations 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections of fingers 
 
Clinical stage 3 
Conditions where a presumptive diagnosis can be made on the basis of clinical 
signs or simple investigations 
Severe weight loss (>10% of presumed or measured body weight) 
Unexplained chronic diarrhoea for longer than one month 
Unexplained persistent fever (intermittent or constant for longer than one month) 
Oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis (TB) diagnosed in last two years 
Severe presumed bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone or 
joint infection, meningitis, bacteraemia) 













Clinical stage 4 
Conditions where a presumptive diagnosis can be made on the basis of clinical 
signs or simple investigations 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe or radiological bacterial pneumonia 






Central nervous system (CNS) toxoplasmosis 
HIV encephalopathy 
 
Conditions where confirmatory diagnostic testing is necessary: 
Extrapulmonary cryptococcosis including meningitis 
Disseminated non-tuberculous mycobacteria infection 
Progressive multifocal leukoencephalopathy (PML) 
Candida of trachea, bronchi or lungs 
Cryptosporidiosis 
Isosporiasis 
Visceral herpes simplex infection 
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or 
lymph nodes) 
Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis) 
Recurrent non-typhoidal salmonella septicaemia 
Lymphoma (cerebral or B cell non-Hodgkin) 









E. WHO Recommendations for second line antiretroviral therpy for adults  
• Second line antiretroviral Second-line ART for adults should consist of two 
nucleoside reverse-transcriptase inhibitors (NRTIs) + a ritonavir-boosted protease 
inhibitor (PI). 
o The following sequence of second-line NRTI options is recommended: 
o After failure on a TDF + 3TC (or FTC)–based first-line regimen, use AZT + 
3TC as the NRTI backbone in second-line regimens. 
o After failure on an AZT or d4T + 3TC–based first-line regimen, use TDF + 
3TC (or FTC) as the NRTI backbone in second-line regimens. 
o Use of NRTI backbones as a fixed-dose combination is recommended as the 
preferred approach (strong recommendation, moderate-quality evidence). 
• Heat-stable fixed-dose combinations of ATV/r and LPV/r are the preferred boosted PI 
options for second-line ART. (strong recommendation, moderate-quality evidence). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
